Seattle Genetics, Inc. today highlighted clinical data from two antibody-drug conjugate programs in development by Genentech, a member of the Roche Group that utilize Seattle Genetics' technology.
http://www.businesswire.com/news/topix/20121211005238/en
http://www.businesswire.com/news/topix/20121211005238/en
No comments:
Post a Comment